A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available CDC-like Kinase inhibitor, BH-30236, in adults with R/R AML or HR-MDS Meeting Abstract
| Authors: | Stein, E. M.; Boussi, L.; Mims, A.; Watts, J. M.; Mannis, G. N.; Liu, H.; Sallman, D.; Ravandi, F.; Schiller, G. J.; Wang, E. S.; Ball, B. J.; Cui, J. J.; Zhou, J.; Graber, A.; Zimmerman, Z.; Strickland, S. A. |
| Abstract Title: | A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available CDC-like Kinase inhibitor, BH-30236, in adults with R/R AML or HR-MDS |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 5999 |
| Language: | English |
| ACCESSION: | WOS:001410643200049 |
| DOI: | 10.1182/blood-2024-204046 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work